Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC cut its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 3.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 35,507 shares of the company’s stock after selling 1,201 shares during the period. Nisa Investment Advisors LLC’s holdings in Henry Schein were worth $2,688,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in HSIC. McGlone Suttner Wealth Management Inc. acquired a new position in Henry Schein in the 4th quarter valued at about $39,000. Baystate Wealth Management LLC grew its holdings in shares of Henry Schein by 2,500.0% in the third quarter. Baystate Wealth Management LLC now owns 520 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares in the last quarter. Neo Ivy Capital Management acquired a new stake in Henry Schein during the 3rd quarter worth approximately $46,000. Covestor Ltd boosted its position in Henry Schein by 88.4% in the 1st quarter. Covestor Ltd now owns 861 shares of the company’s stock valued at $75,000 after buying an additional 404 shares during the period. Finally, RVW Wealth LLC acquired a new position in shares of Henry Schein in the third quarter worth $104,000. 96.62% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Henry Schein

In related news, CEO Bradford C. Connett sold 6,430 shares of the stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total transaction of $477,620.40. Following the sale, the chief executive officer now owns 73,108 shares of the company’s stock, valued at $5,430,462.24. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Henry Schein news, CEO Bradford C. Connett sold 6,430 shares of the stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total transaction of $477,620.40. Following the transaction, the chief executive officer now owns 73,108 shares of the company’s stock, valued at approximately $5,430,462.24. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $74.37, for a total value of $216,193.59. Following the transaction, the insider now owns 209,562 shares in the company, valued at $15,585,125.94. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Henry Schein Stock Down 1.1 %

Shares of Henry Schein stock opened at $71.01 on Friday. Henry Schein, Inc. has a one year low of $60.01 and a one year high of $85.39. The company has a market cap of $9.12 billion, a P/E ratio of 22.54, a PEG ratio of 1.78 and a beta of 0.87. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.67. The firm has a fifty day moving average of $74.81 and a two-hundred day moving average of $72.58.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $0.66 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.04). Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. The company had revenue of $3.02 billion during the quarter, compared to analysts’ expectations of $3 billion. During the same quarter in the prior year, the business earned $1.21 EPS. The business’s revenue for the quarter was down 10.5% compared to the same quarter last year. On average, analysts forecast that Henry Schein, Inc. will post 5.07 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on HSIC shares. Barrington Research upped their target price on shares of Henry Schein from $82.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 28th. Leerink Partnrs reissued a “market perform” rating on shares of Henry Schein in a report on Monday, February 26th. TheStreet raised Henry Schein from a “c+” rating to a “b-” rating in a report on Monday, February 26th. Jefferies Financial Group increased their price objective on Henry Schein from $74.00 to $81.00 and gave the company a “hold” rating in a report on Wednesday, March 6th. Finally, JPMorgan Chase & Co. raised their target price on Henry Schein from $82.00 to $88.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $81.09.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.